Optum, Inc.
12
0
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
8.3%
1 terminated/withdrawn out of 12 trials
87.5%
+1.0% vs industry average
17%
2 trials in Phase 3/4
29%
2 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Examining the Impact of a Digital Health Program and TENS Device for Patients With Chronic Low Back Pain
Role: collaborator
Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
Role: collaborator
The COPD CARE Study: Evaluating the Impact of a Virtual-First COPD Service on Major Cardiac and Respiratory Events
Role: collaborator
Denosumab Safety Assessment in Multiple Observational Databases
Role: collaborator
Research and Innovation to Stop E-cigarette/Vaping in Young Adults
Role: collaborator
Prospective Electronic Polygenic Risk Study - Second Phase
Role: collaborator
Incidence and Predictors of Opioid Overdose and Death Among Long-Term Users of Opioid Analgesics
Role: collaborator
At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19
Role: collaborator
Dapagliflozin Patient Satisfaction Survey
Role: collaborator
American Indians STOp Smoking by Mobile Phone
Role: collaborator
Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Treatment With Dapagliflozin Versus Sitagliptin: An Analysis of Commercial Claims and Linked Laboratory Data
Role: collaborator
Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer
Role: collaborator
All 12 trials loaded